ALLERGOLOGIA ET IMMUNOPATHOLOGIA is a distinguished academic journal dedicated to the field of immunology and allergy, published by CODON PUBLICATIONS, based in Singapore. With its ISSN 0301-0546 and E-ISSN 1578-1267, this journal aims to provide an open platform for researchers and practitioners to share their findings, emphasizing topics related to immunopathology and respiratory health. Covering a broad scope from 1973 to 2024, it currently holds a notable position in several category quartiles, including Q3 in Immunology and Allergy, and Q3 in Pulmonary and Respiratory Medicine as of 2023. Despite the absence of an open access option, the journal maintains an essential role in disseminating pivotal research, reflected in its Scopus rankings that position it within the core of its discipline. With an impact factor acknowledging the significance of its contributions, ALLERGOLOGIA ET IMMUNOPATHOLOGIA continues to be a vital resource for ongoing education and advancement in immunological and allergic research.

The Journal of Cutaneous Immunology and Allergy, published by FRONTIERS MEDIA SA in Switzerland, is an esteemed Open Access platform dedicated to advancing research in the intersecting fields of dermatology, immunology, and allergy. Since its inception in 2018, this journal has provided a vital resource for the dissemination of innovative research findings and critical reviews, enhancing our understanding of cutaneous conditions related to immune responses. Although currently classified in the Q4 quartile in both Dermatology and Immunology & Allergy categories as of 2023, the journal continues to strive for recognition within the scientific community, encouraging collaboration and knowledge sharing among researchers, clinicians, and experts. The journal boasts an E-ISSN of 2574-4593 and is committed to making high-quality research freely accessible to all, thus fostering greater insights into the complexities of skin-related immune disorders. Join us in this journey to explore the forefront of cutaneous research and contribute to the evolving dialogue in this dynamic field.

ANNALS OF CLINICAL AND LABORATORY SCIENCE, published by the Association of Clinical Scientists, is a pivotal journal in the fields of clinical biochemistry, hematology, immunology, and medical laboratory technology. Since its inception in 1971, this journal has become a vital resource for researchers and practitioners aiming to advance their knowledge and skills in laboratory sciences. Although currently not an open access journal, its rich repository of peer-reviewed articles and studies contributes significantly to the academic discourse in diagnostic and therapeutic practices. The journal is categorized in various quartiles, reflecting its impact and contributions to multiple scientific domains, such as Q4 in Clinical Biochemistry and Q3 in Pathology and Forensic Medicine as of 2023. With an extensive convergence of years up to 2024, it proves to be a timeless source for emerging trends and research innovations. The ANNALS OF CLINICAL AND LABORATORY SCIENCE not only supports the professional development of its readers but also encourages interdisciplinary collaboration, making it an essential tool for professionals, students, and researchers dedicated to improving health outcomes through advanced laboratory sciences.

Immunopathologia Persa, published by NIKAN RESEARCH INST, is a premier open-access journal specializing in the fields of immunology, hematology, and endocrinology. Since its inception in 2015, the journal has aimed to disseminate high-quality research and innovative insights critical to understanding immune responses, disease mechanisms, and therapeutic strategies. Based in Iran, the journal contributes significantly to the academic landscape, with quarterly categorizations placing it in the fourth quartile across multiple vital sectors including Endocrinology, Diabetes and Metabolism, and Immunology. It features a diverse range of articles and studies that cater to both emerging and established researchers, aiding in the advancement of knowledge and clinical practice in immunopathology. With its commitment to open access, Immunopathologia Persa ensures that cutting-edge research is readily available to all, fostering a collaborative research environment and promoting the dissemination of findings globally. Researchers, professionals, and students are encouraged to explore the contents of this journal to stay abreast of the latest developments in these critical areas of health science.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

JOURNAL OF AUTOIMMUNITY, published by Academic Press Ltd - Elsevier Science Ltd, stands as a leading authority in the field of immunology, boasting an impressive impact factor and recognized as a Q1 journal in both Immunology and Immunology and Allergy disciplines. Since its inception in 1988, this esteemed journal has provided an essential platform for the dissemination of groundbreaking research, covering a wide spectrum of topics related to autoimmune diseases and their underlying mechanisms. With a strong Scopus ranking, placing it within the top 10% of journals in its field, the JOURNAL OF AUTOIMMUNITY fosters collaborations among researchers, clinicians, and academics, thereby enriching the global discourse on autoimmune health. Although it does not offer open access, it remains a vital resource for those seeking in-depth analysis and innovative findings that drive forward knowledge and therapeutic advancements in immunology.

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

AUTOIMMUNITY, published by Taylor & Francis Ltd, is an influential journal dedicated to advancing the understanding of autoimmune diseases through rigorous research and scholarly discourse. With an ISSN of 0891-6934 and an E-ISSN of 1607-842X, this journal serves as a key resource for immunologists, medical professionals, and students engaged in investigating the complex mechanisms underpinning autoimmunity. Operating from the United Kingdom, it offers valuable insights into immunological and allergic phenomena, achieving respectable Scopus rankings in both Immunology and Allergy (106/233, Q3) and Immunology and Microbiology (125/236, Q2). Covering a broad spectrum of topics since its inception in 1988, AUTOIMMUNITY encourages the dissemination of innovative research findings and aims to enhance collaborative efforts within the field. While it currently adopts a conventional access model, the journal's commitment to quality and excellence positions it as a vital platform for those looking to engage with cutting-edge research in immunology.

Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.